These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19483491)

  • 1. High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission.
    Yeh YW; Chen CH; Kuo SC; Wang SC; Chen CK; Feng HM
    Clin Neuropharmacol; 2009; 32(3):174-6. PubMed ID: 19483491
    [No Abstract]   [Full Text] [Related]  

  • 2. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series.
    Dell'osso B; Mundo E; Marazziti D; Altamura AC
    J Psychopharmacol; 2008 Mar; 22(2):210-3. PubMed ID: 18208931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.
    Dougherty DD; Corse AK; Chou T; Duffy A; Arulpragasam AR; Deckersbach T; Jenike MA; Keuthen NJ
    Int J Neuropsychopharmacol; 2015; 18(2):. PubMed ID: 25637377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful duloxetine treatment of a binge eating disorder: a case report.
    Bernardi S; Pallanti S
    J Psychopharmacol; 2010 Aug; 24(8):1269-72. PubMed ID: 19010975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
    Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptom remission in OCD after discontinuation of pharmacotherapy with fluoxetine: a case for looking beyond serotonin.
    Zurowski B; Wahl K; Hohagen F; Kordon A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):959-60. PubMed ID: 17321024
    [No Abstract]   [Full Text] [Related]  

  • 9. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
    Mowla A; Boostani S; Dastgheib SA
    J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine hydrochloride.
    Waitekus AB; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Nov; 3(11):907-8. PubMed ID: 15558861
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: a case report.
    Hazen E; Fava M
    J Psychopharmacol; 2006 Sep; 20(5):723-4. PubMed ID: 16401659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study.
    Perahia DG; Gilaberte I; Wang F; Wiltse CG; Huckins SA; Clemens JW; Montgomery SA; Montejo AL; Detke MJ
    Br J Psychiatry; 2006 Apr; 188():346-53. PubMed ID: 16582061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
    Lee SI; Keltner NL
    Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
    [No Abstract]   [Full Text] [Related]  

  • 14. Duloxetine in the treatment of social anxiety disorder.
    Crippa JA; Filho AS; Freitas MC; Zuardi AW
    J Clin Psychopharmacol; 2007 Jun; 27(3):310. PubMed ID: 17502786
    [No Abstract]   [Full Text] [Related]  

  • 15. Venlafaxine treatment of obsessive-compulsive disorder: case reports.
    Marazziti D
    CNS Spectr; 2003 Jun; 8(6):421-2. PubMed ID: 12858131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible dose-response relationship for risperidone in obsessive-compulsive disorder.
    Baker RW
    J Clin Psychiatry; 1998 Mar; 59(3):134. PubMed ID: 9541161
    [No Abstract]   [Full Text] [Related]  

  • 17. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, tolerability, and safety of duloxetine.
    Wise TN
    CNS Spectr; 2005 Dec; 10(12 Suppl 19):10-1. PubMed ID: 18841598
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of lithium and duloxetine in 2 depressed patients refractory to duloxetine monotherapy.
    Steffenhagen N; Kürstein B; Kirkby KC; Himmerich H
    Pharmacopsychiatry; 2011 Mar; 44(2):72-4. PubMed ID: 21161884
    [No Abstract]   [Full Text] [Related]  

  • 20. First preliminary results of a single case report: duloxetine might improve some symptoms of attention-deficit hyperactivity disorder.
    Niederhofer H
    Eur Psychiatry; 2010 May; 25(4):214-5. PubMed ID: 19800768
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.